

June 16, 2025

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

#### Sub: Analysts/Institutional Investors - presentation

This has reference to the virtual connect with analysts/ institutional investors to be held today, Monday, June 16, 2025 at 2:30 p.m. (IST).

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is the presentation for the above meeting with analysts/ institutional investors.

Thanking you.

For Procter & Gamble Health Limited

Zeal Rupani Company Secretary



# P&G Health

Investor and Analyst Connect 16 June 2025

### **Disclaimer**

This communication, except for the historical data, may contain forward-looking statements, including words, phrases, numbers that set forth anticipated results based on management's current plans and assumptions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and uncertainties that may cause results to differ materially from those expressed or implied in those statements. The Company cautions investors that any such forward-looking statements are not guarantees of future performance and that actual events or results may differ materially from those statements. Actual events or results may differ materially because of factors that affect international businesses and global economic conditions, as well as matters specific to the Company and the markets it serves. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, except to the extent required by law.





# P&G Health

Investor and Analyst Connect 16 June 2025

# FISCAL RESULTS

2024-25

## **DELIVERED A STRONG YEAR**

FY 2024-25 | Strong, balanced growth over the 9-month fiscal versus comparable past period





Considering that the company, effective this year, changed its Financial Year from July 1 – June 30 to April 1 – March 31, the current Financial Year of the Company covers a period of 9 months, from July 1, 2024, to March 31, 2025. The company performance has therefore been indexed versus the comparable 9-month period in the last year (July 1, 2023, to March 31, 2024). The performance versus a 12-month past fiscal will not be comparable.

# INTEGRATED GROWTH STRATEGY SUSTAINED EXCELLENCE



### **PORTFOLIO**

PERFORMANCE DRIVES

BRAND CHOICE



#### **ORGANIZATION**

EMPOWERED • AGILE ACCOUNTABLE



#### **SUPERIORITY**

TO WIN WITH CONSUMERS



# CONSTRUCTIVE DISRUPTION

**ACROSS OUR BUSINESS** 



# **PRODUCTIVITY**TO FUEL INVESTMENTS







# **PORTFOLIO**

PERFORMANCE DRIVES BRAND CHOICE

## TRUSTED, QUALITY, HIGHLY RECOMMENDED BRANDS



NEUROBIO affa D











Nasivio







# **SUPERIORITY**TO WIN WITH CONSUMERS

# SUPERIORITY ACROSS 5 VOS\* TO WIN WITH CONSUMERS













\*Vectors of Superiority

# INTEGRATING VECTORS OF SUPERIORITY

### **NEUROBION**

Superior **Product** 



Superior **Communication** 



Superior **Packaging** 



Superior Customer Value






Superior **Retail Execution** 







# **INTEGRATING VECTORS OF SUPERIORITY EVION**

**Product** 

Superior **Customer Value** 



Superior Communication

UNPAUSE

Evion



Superior **Retail Execution** 










Vitamin E Capsules USP 400 mg Evion

Superior

**Packaging** 





# CONSTRUCTIVE DISRUPTION

**ACROSS THE BUSINESS** 

# **SEEDING FOR THE FUTURE**





Rural Coverage Expansion



# Leveraging E-Commerce









## **PRODUCTIVITY**

TO FUEL INVESTMENTS

# PRODUCTIVITY INTEGRATED INTO THE STRATEGY

Delivering the same or better output measures...

with lower spending or resource investment.





INR 40 crores productivity savings for FY 24/25

Business Use



## **ORGANIZATION**

EMPOWERED · AGILE ACCOUNTABLE




# **COMMUNITY IMPACT**

PUBLIC HEALTH & ACCESS

### **TOWARDS BUILDING A HEALTHIER INDIA**

### **ENABLING LAST MILE ACCESS TO HEALTH**









MOBILE HEALTHCARE UNITS
Across 8 States



### **TOWARDS BUILDING A HEALTHIER INDIA**

### **COMMUNITY INTERVENTIONS & BEHAVIORAL CHANGE**



**Yes to POSHAN** 



**Xotej Jeeban** 




**Arogya Sakhis** 



Swasthya Sakhi



**Maternal & Child Health | Nutrition | Anemia Prevention** 



# INTEGRATED GROWTH STRATEGY SUSTAINED EXCELLENCE



### **PORTFOLIO**

PERFORMANCE DRIVES

BRAND CHOICE



#### **ORGANIZATION**

EMPOWERED • AGILE ACCOUNTABLE



#### **SUPERIORITY**

TO WIN WITH CONSUMERS



CONSTRUCTIVE DISRUPTION

**ACROSS OUR BUSINESS** 




PRODUCTIVITY
TO FUEL INVESTMENTS



# LONG TERM TRENDS

# **SUPERIOR RESULTS OVER THE P5Y**






Note: 1) Basis Published results; 2) Net Sales refers to revenue from operations; 3) PAT Excluding OCI; 4) ROE = PAT/ Avg. Equity; 5) Sales/ PAT of 2020 was 18 month period and hence above numbers are adjusted for 12-month estimates

## **SUPERIOR RESULTS OVER THE P5Y**



\* Note: FY 24-25 was a 9-month year and hence above numbers are adjusted for 12-month estimates; Sales of 2020 was 18 month period and hence above numbers are adjusted for 12-month estimates



\* Note: FY 24-25 was a 9-month year and hence above numbers are adjusted for 12month estimates; PAT of 2020 was 18 month period and hence above numbers are adjusted for 12-month estimates



#### **Business Use**

# **CREATING SUPERIOR SHAREHOLDER VALUE**






# LANDSCAPE




### Accelerating VMS category & emerging trends in India










## Growing <u>liver disease burden</u> in India with high 38% prevalence!



% represent population suffering from these conditions